Noema Pharma AG extends Series B financing
Swiss Noema Pharma AG has cashed in a CHF27m extention to its Series B financing that is used to advance four Phase II programmes in neurology.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2054 entries already.
Entries by Thomas Gabrielczyk
Citryll BV raises €85m in Series B financing
Dutch inflammation specialist Citryll BV has raised €85m to push clininal testing of its lead candidate, CIT-013, a bifunctional antibody that prevents the release of neutrophil extracellular traps (NETs) from neutrophil granulocytes into the cytoplasm, thus blocking inflammatory and autoimmune diseases at its very roots.
UK first country in Europe to reimburse tirzepatide
The British NICE has defined the conditions for the reimbursement of Eli Lilly’s obesity blockbuster tirzepatide. This makes the UK the first country in which patients do not have to pay for the drug out of their own pocket.
French Ipsen inks US$610m biobucks deal with Biomunex SA
French Ipsen has exclusively licensed BMX-502, a T-cell engager (TCE) from Biommunex SA, which prevents common problems of TCEs such as cytokine release syndrome and T cell exhaustion by using a specific mucosal T cell subpopulation abundant in the human body.
Obesity gene therapy enters Phase I testing
After securing an equity investment from French pharma giant Sanofi, Italian gene therapy company Resalis Therapeutics srl has begun enrolling participants for a Phase I study of its obesity gene therapy, RES-010, which converts white adipocytes into brown adipocytes.
European Biotechnology and SLAS seal partnership
The Society for Laboratory Automation & Screening (SLAS) has selected the European Biotechnology Magazine as its official media partner.
Biopharma transformation: growing impact of automation
New AI tools and drug screening based on human cells and organoids promise a quantum leap in the success rate of drug development and in the processing of data from high-throughput analyses as well as a revolution in diagnostics. The SLAS Europe 2024 conference in Barcelona highlighted the latest advances set to transform the entire biopharma sector.
Breakthrough: Bio-based foam absorbs 99% of microplastics
Chinese researchers headed by Prof. Dr. Hongbing Deng from Wuhan University report they were able to absorb up to 99.9% of microplastics in water, which could help solve one of the most pressing environmental problems.
Roche makes takeover bid for Poseida Therapeutics Inc
Genentech, the US arm of Swiss-based Roche AG, plans to acquire its long-time partner in allogeneic CAR-T blood cancer and gene therapies, Poseida Therapeutics Inc, for up to US$1.5bn.
EC ordered to pay cost of PharmaMar vs EMA case
The General Court of the EU orders the European Commission to pay the costs in the case of Aplidin® against the Spanish company PharmaMar SA, in which an EU marketing authorisation was not granted due to conflict-of-interests within the CHMP of the European Medicines Agency.